StockNews.com upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning. Separately, Oppenheimer upped their price objective on shares of Corbus Pharmaceuticals from $20.00 to $51.00 and gave the company an outperform rating in a research note on […]
StockNews.com upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a sell rating to a hold rating in a research note published on Saturday. Separately, Oppenheimer raised their price target on Corbus Pharmaceuticals from $20.00 to $51.00 and gave the stock an outperform rating in a research report on Monday, January 29th. Get Our […]
Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price objective increased by Oppenheimer from $20.00 to $51.00 in a research note published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on shares of Corbus Pharmaceuticals in a research report on Friday, January 26th. They […]
StockNews.com started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report sent to investors on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Corbus Pharmaceuticals Trading Up 6.5 % NASDAQ:CRBP opened at $6.16 on Monday. The company has a market capitalization of $27.25 million, a P/E […]
Equities researchers at StockNews.com started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. Corbus Pharmaceuticals Stock Up 3.6 % Shares of CRBP stock opened at $5.50 on Monday. The business has a 50 […]